तुलना करने के लिए मीट्रिक्स | 196170 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध196170पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | 109.9x | −21.1x | −0.4x | |
PEG अनुपात | 0.99 | 0.21 | 0.00 | |
क़ीमत/बुक | 39.3x | 2.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 82.9x | 7.6x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 22.2% | 46.6% | 49.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 7.3% | 7.0% | अनलॉक करें |
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.